Anika Therapeutics, Inc.
ANIK
$14.88
-$0.14-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.28% | 10.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.28% | 10.06% | |||
| Cost of Revenue | -7.18% | -6.52% | |||
| Gross Profit | -0.95% | 23.07% | |||
| SG&A Expenses | 47.11% | 1.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.12% | -3.48% | |||
| Operating Income | -949.54% | 119.98% | |||
| Income Before Tax | -731.02% | 134.17% | |||
| Income Tax Expenses | 122.66% | -210.44% | |||
| Earnings from Continuing Operations | -380.73% | 156.72% | |||
| Earnings from Discontinued Operations | -- | -278.37% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,831.51% | 112.54% | |||
| EBIT | -949.54% | 119.98% | |||
| EBITDA | -307.79% | 207.32% | |||
| EPS Basic | -1,922.93% | 112.69% | |||
| Normalized Basic EPS | -764.78% | 134.57% | |||
| EPS Diluted | -2,480.25% | 109.72% | |||
| Normalized Diluted EPS | -783.13% | 133.64% | |||
| Average Basic Shares Outstanding | -5.20% | -1.01% | |||
| Average Diluted Shares Outstanding | -7.76% | 1.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||